Rani Therapeutics Holdings, Inc.
PosiFunda Ratios Only on PositoAI
PositoAI's own ratios from Rani Therapeutics Holdings, Inc.'s yearly results (2022–2025), compared with Healthcare companies in United States. Tap ? on any ratio for what it means.
Where $100 of sales goes
Latest year (Dec 2025). Taxes and other income are not shown, so the parts need not add up to 100.
Cash quality
Profit Cash Ratio
—Loss-making or profit too small
Over the last 3 years profit was a loss or under 2% of sales, so cash per 100 of profit is not meaningful.
Self-Funding Ratio
-66.5×Over the last 3 years operating cash was negative while the company kept spending on investment (capex).
Lower than 77% of Healthcare companies in United States.
Cash Locked Ratio
—Data incomplete
Growth quality
Steadiness Ratio
2/3 · 2/3Sales grew in 2 of the last 3 years; profit grew in 2 of 3.
Steadier than 69% of Healthcare companies in United States.
Growth Efficiency Ratio
—Data incomplete
Asset Productivity Ratio
—Data incomplete
Balance-sheet strength
Debt Due Cover Ratio
-11.8×Operating cash was negative last year, while some debt falls due within a year.
Higher than 53% of Healthcare companies in United States.
Cash Cushion Ratio
+55%Cash, after subtracting all debt, equals 55% of its market value (net cash).
Higher than 78% of Healthcare companies in United States.
Tangible Assets Ratio
—Data incomplete
Tangible Net Worth Ratio
—Data incomplete
Shareholders
Standard fundamentals
P/E, P/B, ROE, debt, growth and more (13)
Rani Therapeutics Holdings, Inc. made a loss over the last year. Rani Therapeutics Holdings, Inc. owes $0.21 for every $1 it owns. Rani Therapeutics Holdings, Inc. made a loss in each of the last two years.
Compared with Healthcare companies in United States · latest annual results Dec 2025.
P/E ratio
LossRani Therapeutics Holdings, Inc. made a loss over the last year, so its P/E ratio is not meaningful.
P/B ratio
2.10The share price is 2.10 times Rani Therapeutics Holdings, Inc.'s book value per share, lower than 57% of Healthcare companies in United States.
Market cap
$83 MThe total market value of all of Rani Therapeutics Holdings, Inc.'s shares at today's price (share price × number of shares), smaller than 68% of Healthcare companies in United States. PosiCap size class: Micro Cap.
Net worth (book value)
$39 MWhat Rani Therapeutics Holdings, Inc. would have left on paper if it sold everything it owns and paid everything it owes, from its latest balance sheet (30 Jun 2026).
Book value per share
$0.28Net worth divided by the number of shares. The share price of $0.59 is 2.1 times this, which is the P/B above.
Return on equity (ROE)
-172.2%Rani Therapeutics Holdings, Inc. lost 172.2% of its shareholders' money over the last year, lower than 82% of Healthcare companies in United States.
Owes vs Owns
0.21×Rani Therapeutics Holdings, Inc. owes $0.21 for every $1 it owns (low), lower than 71% of Healthcare companies in United States.
Dividend yield
NoneRani Therapeutics Holdings, Inc. does not currently pay a dividend.
Revenue growth
+59%Revenue rose 59% in the year to Dec 2025.
Profit growth
LossRani Therapeutics Holdings, Inc. made a loss in each of the last two years.
Profit margin
-1817.1%Rani Therapeutics Holdings, Inc. lost $1817 for every $100 of revenue.
Interest cover
Not coveredRani Therapeutics Holdings, Inc.'s operating profit did not cover its interest costs in the year to Dec 2025.
Cash vs debt
Net cashRani Therapeutics Holdings, Inc. held $45 M more cash than debt (net cash) at Dec 2025.
Questions
How is P/B calculated on PositoAI?
P/B is market cap divided by net worth from the latest balance sheet. For Rani Therapeutics Holdings, Inc.: $83 M ÷ $39 M (30 Jun 2026) = 2.1.
What is Rani Therapeutics Holdings, Inc.'s return on equity?
Rani Therapeutics Holdings, Inc. lost 172.2% of its shareholders' money over the last year, lower than 82% of Healthcare companies in United States.
How much does Rani Therapeutics Holdings, Inc. owe compared with what it owns?
Rani Therapeutics Holdings, Inc. owes $0.21 for every $1 it owns (low), lower than 71% of Healthcare companies in United States.
Does Rani Therapeutics Holdings, Inc. pay a dividend?
No. Rani Therapeutics Holdings, Inc. does not currently pay a dividend.
Is Rani Therapeutics Holdings, Inc.'s revenue growing?
Revenue rose 59% in the year to Dec 2025.
Figures from the company's yearly results and PositoAI's own data. Full tables are on the Go Deep tab. What each figure means. PositoAI is for research and education only and is not investment advice.